Samuel Congello, DO
Interventional Cardiology · Mason City, IANPI 1609869254
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 555 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Boston Scientific at 26.6% of the total. Reporting peaked in 2019 at $3,595 and has fallen 50.6% since, to $1,774 in 2025.
Across 555 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Abiomed$2K
- Abbott$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- AstraZeneca$812
- Medtronic$710
- plus $3K from 26 others
What the payments were for
- Travel & lodging$5293%
- Food & beverage$14,34395%
- Education$2842%
- Gifts$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 146 | $4,032 |
| Abiomed | 39 | $2,403 |
| Abbott | 83 | $2,329 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 95 | $1,411 |
| AstraZeneca | 18 | $812 |
| Medtronic(2 entities) | 22 | $710 |
| Novartis | 40 | $677 |
| E.r. Squibb & Sons, L.L.C. | 25 | $417 |
| Boehringer Ingelheim | 9 | $307 |
| Biosense Webster, Inc. | 11 | $281 |
| Johnson & Johnson | 17 | $239 |
| Shockwave Medical, Inc | 6 | $189 |
| Actelion Pharmaceuticals US, Inc. | 2 | $145 |
| Edwards Lifesciences | 2 | $132 |
| Getinge USA Sales, LLC | 4 | $129 |
| Cardiovascular Systems Inc. | 2 | $126 |
| Merck | 5 | $111 |
| Teleflex LLC | 3 | $102 |
| Philips North America LLC | 3 | $93 |
| Sanofi-aventis U.S. LLC | 2 | $80 |
| Atricure, Inc. | 1 | $77 |
| Regeneron Healthcare Solutions, Inc. | 5 | $62 |
| Impulse Dynamics (USA) Inc. | 1 | $56 |
| Bridgebio Pharma, Inc. | 3 | $55 |
| Cook Medical LLC | 4 | $53 |
| Bard Peripheral Vascular, Inc. | 1 | $37 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Bayer | 1 | $21 |
| Nuwellis, Inc. | 1 | $19 |
| Pfizer | 1 | $14 |
| Bracco Diagnostics Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,172 in reported general payments places this provider in the 75th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $108,295 |
| XareltoRivaroxaban | 57 | $32,412 |
| EntrestoSacubitril/Valsartan | 38 | $28,752 |
| FarxigaDapagliflozin Propanediol | 38 | $18,999 |
| JardianceEmpagliflozin | 28 | $18,502 |
| BrilintaTicagrelor | 17 | $14,877 |
| Repatha SureclickEvolocumab | 19 | $10,493 |
| Ranolazine ErRanolazine | 32 | $7,570 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 255 | $5,034 |
| Metoprolol Succinate | 330 | $4,986 |
| ClopidogrelClopidogrel Bisulfate | 319 | $2,989 |
| Prasugrel Hcl | 32 | $1,969 |
| Torsemide | 57 | $1,519 |
| Pantoprazole Sodium | 96 | $1,415 |
| Ezetimibe | 32 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $108,295114 claims |
| AstraZenecaFarxiga, Brilinta | $812 | $33,87655 claims |
| Johnson & JohnsonXarelto | $239 | $32,41257 claims |
| NovartisEntresto | $677 | $28,75238 claims |
| Boehringer IngelheimJardiance | $307 | $18,50228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Mason City
- Fayez SiddiquiMason City$21K
- Richard RattinMason City$15K
- James ReederMason City$1K
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Srikanth KasulaDavenport$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.